approach to the prediction of nsclc patient response to treatment with an egfr tk inhibitor

• 1. 一种判断NSCLC患者对吉非替尼治疗反应性的试剂盒 [P] . 中国专利： CN104131102B . 2016.06.15
• 2. 一种判断NSCLC患者对吉非替尼治疗反应性的试剂盒 [P] . 中国专利： CN104131102A . 2014-11-05
• 3. approach to the prediction of nsclc patient response to treatment with an egfr tk inhibitor [P] . DK2413142T3 . 2013-07-22

  机译： NSCLC患者对egfr tk抑制剂治疗反应的预测方法

• 4. approach to the prediction of nsclc patient response to treatment with an egfr tk inhibitor [P] . DK2114990T5 . 2012-05-07

  机译： NSCLC患者对egfr tk抑制剂治疗反应的预测方法

• 5. Method for predicting the response of NSCLC patients to treatment with an EGFR inhibitor-tk [P] . ES2412432T3 . 2013-07-11

  机译： 预测NSCLC患者对EGFR抑制剂-tk治疗的反应的方法

• 1. Systemic treatment in EGFR-ALK NSCLC patients：second line therapy and beyond [J] . Niki Karachaliou, Rafael Rosell 癌症生物学与医学：英文版 . 2014,第003期
• 2. Systemic treatment in EGFR-ALK NSCLC patients：second line therapy and beyond [J] . Niki Karachaliou, Rafael Rosell 癌症生物学与医学（英文版 ） . 2014,第003期
• 3. Validation of [ 18F]FLT as a perfusion-independent imaging biomarker of tumour response in EGFR-mutated NSCLC patients undergoing treatment with an EGFR tyrosine kinase inhibitor [J] . R. Iqbal, G. M. Kramer, V. Frings, EJNMMI Research . 2018,第1期
• 4. The role of neuron-specific enolase (NSE) and thymidine [corrected] kinase (TK) levels in prediction of efficacy of EGFR-TKIs in patients with advanced-stage NSCLC. [J] . Ondrej Fiala, Milos Pesek, Jindrich Finek, Anticancer Research: International Journal of Cancer Research and Treatment . 2014,第9期
• 5. The Role of Neuron-specific Enolase (NSE) and Thimidine Kinase (TK) Levels in Prediction of Efficacy of EGFR-TKIs in Patients with Advanced-stage NSCLC (vol 34, pg 5193, 2014) [J] . Fiala O. Anticancer Research: International Journal of Cancer Research and Treatment . 2014,第12期
• 6. PET/CT Radiomic Sequencer for Prediction of EGFR and KRAS Mutation Status in NSCLC Patients [C] . I. Shiri, H. Maleki, G. Hajianfar, IEEE Nuclear Science Symposium;Medical Imaging Conference . 2018
• 7. Exploitation and mechanistic validation of drug-combination strategies to overcome EGFR-inhibitor resistance in NSCLC cells [D] . Wang, Yu-Chieh. 2008
• 8. Validation of 18FFLT as a perfusion-independent imaging biomarker of tumour response in EGFR-mutated NSCLC patients undergoing treatment with an EGFR tyrosine kinase inhibitor [O] . R. Iqbal, G. M. Kramer, V. Frings, 2018
• 9. Early Prediction of Response to Tyrosine Kinase Inhibitors by Quantification of EGFR Mutations in Plasma of NSCLC Patients [O] . Marchetti Antonio, Palma John F., Felicioni Lara, 2015

• 1. FDG-PET/CT response evaluation during EGFR-TKI treatment in patients with NSCLC [J] . Matthijs H van Gool ,Tjeerd S Aukema ,Koen J Hartemink . 世界放射学杂志：英文版（电子版） . 2014,第7期
• 2. Value of Child-Turcotte-Pugh Score in Prediction of Treatment Response in “Difficult to Treat” Chronic HCV Cirrhotic Patients [J] . Taghrid Mohamed Abdalla ,Sameh M. Abdel Monem ,Hosam M. Dawod . 肠胃病学期刊（英文） . 2019,第11期
• 3. The Predictive Value of On-treatment Virological Response for Sustained Virological Response in Patients with Chronic Hepatitis C Receiving a Personalized Treatment Program [J] . Ming-hui Li ,Cai-qin Mu ,Lei-ping Hu . 国际感染杂志（电子版） . 2013,第002期
• 4. EGFR突变NSCLC患者精准个体化治疗——EGFR-TKIs对19外显子缺失和21外显子点突变患者的疗效是否存在差异 [C] . 胡兴胜 . 第九届中国肿瘤内科大会、第四届中国肿瘤医师大会暨中国抗癌协会肿瘤临床化疗专业委员会2015年学术年会 . 2015
• 5. EGFR阳性脑转移NSCLC患者单药EGFr-TKI和EGFr-TKI联合脑部放疗的预后分析 [A] . 朱倩倩 . 2017